Biotech

All Articles

Neurocrine's KarXT competitor attacks in stage 2-- but just at low dosage

.Neurocrine Biosciences has achieved its own hoped-for profile page in a phase 2 schizophrenia test,...

Vaderis' uncommon blood vessel condition medication lowers nosebleeds

.Vaderis Therapeutics' objective to develop the initial medicine aimed specifically at a specific un...

Navigator brings up $100M to create brand new autoimmune pipeline

.Sat nav Medicines has actually equipped on its own along with $100 thousand in collection A funds a...

Duality finds money for ADC trials as IPO wave infects Asia

.China's Duplicity Biotherapeutics has actually submitted (PDF) paperwork for a Hong Kong IPO, findi...

YolTech sells China rights to genetics editing treatment for $29M

.4 months after Mandarin gene editing provider YolTech Therapies took its own cholesterol disease-fo...

Addex inventory increases after Indivior offers up to $300M for compound

.Indivior is grabbing a little molecule allosteric modulator designed to treat material usage disord...

Molecular Allies tweaks AML test over 'suboptimal visibility'

.Molecular Partners has recognized "suboptimal visibility" to its own tetra-specific T-cell engager ...

Despite blended market, a venture capital revival could be can be found in Europe: PitchBook

.While the biotech investment scene in Europe has reduced somewhat adhering to a COVID-19 backing bo...

8 months after a $213M fundraise, gene publisher Tome produces decreases

.After raising $213 million in 2023-- one of the year's most extensive personal biotech shots-- Volu...

BioMarin builds exec crew with biotech vets-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of substantial management hirings, shootings an...